Infection Prevention

  • It is estimated that 2% to 5% of all patients who undergo surgery will develop a Surgical Site Infection (SSI). These infections are associated with added morbidity, including prolonged hospitalisation by 2 weeks, 5 times the risk of readmission, an increase in average health care costs of up to $26,000 per patient, and twice the risk of death.[1]
  • FloraSeal has been shown to trap and immobilise bacteria that may cause infection to the patient. It rapidly and powerfully kills gram-positive and gram-negative bacteria.[2]
  • FloraSeal effectively reduces microbial colonisation within 15 minutes and maintains a low microbial colonisation throughout the 24 hours after application, has the same efficacy when being used with or without an antimicrobial surgical incise drape, and mitigates microorganisms more effectively than an antimicrobial surgical incise drape alone.[3]

1. Towfigh, S., Cheadle, W. G., Lowry, S. F., Malangoni, M. A., & Wilson, S. E. (2008). Significant reduction in incidence of wound contamination by skin flora through use of microbial sealant. Archives of surgery (Chicago, Ill.:1960), 143(9), 885–891.

2. Prince, D., Kohan, K., Solanki, Z., Mastej, J., Prince, D., Varughese, R., & Patel, M. (2017). Immobilization and death of bacteria by Flora Seal microbial sealant. Int J Pharm Sci Invent, 6(6), 45-49.

3. Data on File. Adhezion Biomedical, LLC

SurgiSeal® Topical Skin Adhesive is a high purity, antimicrobial, liquid topical skin adhesive that can replace sutures for incision or laceration repair.

SurgiSeal® is the only topical skin adhesive in the world to receive FDA 510K Clearance in demonstrating inhibition of gram-positive and gram-negative bacteria growth.[1]

SurgiSeal® provides the optimal balance between strength and flexibility. In replacing sutures for incision or laceration repair, it can save time, provide a flexible, water-resistant, protective coating, and eliminate the need for suture removal.


1. SurgiSeal IFU: Due to the anhydrous property of the SurgiSeal adhesive, gram+ and gram- bacteria which become incorporated within the adhesive upon application, are not expected to grow.

Synvichor is the world’s first genomic PCR test that sets a new medical standard globally for the rapid, accurate and reliable differentiation of joint pain.


Undifferentiated joint pain: a global problem

When a patient presents with a red, hot, swollen and painful joint, reliably differentiating infection from inflammation poses a significant global problem.

Typical wait times for culture results vary from 24hrs to 21 days, with a true positivity of up to 20%, meaning they are inconclusive more than 80% of the time.

Rather than risk missing or misdiagnosing an infection, the current approach sees the patient admitted to hospital and treated with antibiotics.

This results in uncertainty for patients and clinicians, increased costs to the hospital, and poorer outcomes.

Unparalleled speed, precision, and reliability

With up to 95% negative and positive predictive value and results in ~3 hours, Synvichor provides rapid and reliable differentiation of joint pain.

Synvichor helps to rapidly assess which patients require urgent treatment for infection, and which patients can be safely managed in the community for non-infectious inflammation.

Synvichor logo

Enhances your diagnostic speed

Optimises your treatment options

Enables clinicians to safely manage up to two-thirds of patients in the community



Synvichor logo

~ 3 hours

vs current culture testing

24 hours - 21 days



Synvichor logo




vs current culture testing

13-20% accuracy[1]

2. Graue C et al. Open Forum Infect Dis. 2020; 7(Suppl 1):S233–4.

Revolution Surgical Pty Ltd
5/14-16 Crescent Street, Rozelle NSW 2039 AU
ABN: 63 165 643 434

© 2018-2024 Revolution Surgical

Website by: WebInjection